Liver, pancreas, metabolism, diabetes & kidneys

Liver, pancreas & metabolism

Alkahtane AA, Albasher G, Al-Sultan NK, et al. Long-term treatment with finasteride induces apoptosis and pathological changes in female mice. Hum Exp Toxicol. 2019. doi:10.1177/0960327119842195 • PubMed

da Cruz GK, Martins MIM, Antunes FTT, et al. Evaluation of the efficacy and toxicity of oral and topical pumpkin oil on the hair growth of mice. Acta Histochem. 2022. doi:10.1016/j.acthis.2022.151894PubMed [Includes finasteride treatment group]

Duskova M, Hill M, Starka L. Changes of metabolic profile in men treated for androgenetic alopecia with 1 mg finasteride. Endocr Regul. 2010. doi:10.4149/endo_2010_01_3PubMed

Hazlehurst JM, Oprescu AI, Nikolaou N, et al. Dual-5α-reductase inhibition promotes hepatic lipid accumulation in man. J Clin Endocrinol Metab. 2016. doi:10.1210/jc.2015-2928PubMedPMC full text

Kur P, Kolasa-Wołosiuk A, Grabowska M, et al. The postnatal offspring of finasteride-treated male rats shows hyperglycaemia, elevated hepatic glycogen storage and altered GLUT2, IR, and AR expression in the liver. Int J Mol Sci. 2021. doi:10.3390/ijms22031242 • PubMed • PMC full text

Lai SW, Lai HC, Lin CL, Liao KF. Finasteride use and acute pancreatitis in Taiwan. J Clin Pharmacol. 2015. doi:10.1002/jcph.462PubMed

Livingstone DE, Barat P, Di Rollo EM, et al. 5α-reductase type 1 deficiency or inhibition predisposes to insulin resistance, hepatic steatosis, and liver fibrosis in rodents. Diabetes. 2015. doi:10.2337/db14-0249 • PubMed

Martínez de Guzmán M, Martínez-Crespo JJ. Hepatitis por finasterida [Finasteride-induced hepatitis]. Farm Hosp. 2006. Spanish. doi:10.1016/s1130-6343(06)74011-9PubMed

Nasiri M, Nikolaou N, Parajes S, et al. 5α-reductase type 2 regulates glucocorticoid action and metabolic phenotype in human hepatocytes. Endocrinology. 2015. doi:10.1210/en.2015-1149 • PubMed

Rzeszotek S, Kolasa A, Pilutin A, Misiakiewicz-Has K, Sielatycka K, Wiszniewska B. The interplay between finasteride-induced androgen imbalance, endoplasmic reticulum stress, oxidative stress, and liver disorders in paternal and filial generation. Biomedicines. 2022. doi:10.3390/biomedicines10112725PubMed

Traish AM. Health risks associated with long-term finasteride and dutasteride use: It’s time to sound the alarm. World J Mens Health. 2020. doi:10.5534/wjmh.200012 • PubMed • PMC full text

Traish AM. Negative impact of testosterone deficiency and 5α-reductase inhibitors therapy on metabolic and sexual function in men. Adv Exp Med Biol. 2017. doi:10.1007/978-3-319-70178-3_22 • PubMed

Traish AM, Guay AT, Zitzmann M. 5α-reductase inhibitors alter steroid metabolism and may contribute to insulin resistance, diabetes, metabolic syndrome and vascular disease: a medical hypothesis. Horm Mol Biol Clin Investig. 2014. doi:10.1515/hmbci-2014-0025 • PubMed

Traish A, Haider KS, Doros G, Haider A. Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction. Horm Mol Biol Clin Investig. 2017. doi:10.1515/hmbci-2017-0015 • PubMed

Xu W, Schiffer L, Qadir MMF, et al. Intracrine testosterone activation in human pancreatic β-cells stimulates insulin secretion. Diabetes. 2020. doi:10.2337/db20-0228 • PubMed • PMC full text

Diabetes risk

Johnstone J, Lusty A, Tohidi M, et al. The association of new-onset diabetes mellitus and medical therapy for benign prostatic hyperplasia: A population-based study. Can Urol Assoc J. 2021. doi:10.5489/cuaj.7489 • PubMed • PMC full text

Lee SS, Yang YW, Tsai TH, et al. 5-alpha-reductase inhibitors and the risk of diabetes mellitus: A nationwide population-based study. Prostate. 2016. doi:10.1002/pros.23097PubMed

Traish AM, Guay AT, Zitzmann M. 5α-reductase inhibitors alter steroid metabolism and may contribute to insulin resistance, diabetes, metabolic syndrome and vascular disease: a medical hypothesis. Horm Mol Biol Clin Investig. 2014. doi:10.1515/hmbci-2014-0025 • PubMed

Wei L, Lai EC, Kao-Yang YH, Walker BR, MacDonald TM, Andrew R. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study. BMJ. 2019. doi:10.1136/bmj.l1204PubMedPMC full text

Xu W, Schiffer L, Qadir MMF, et al. Intracrine testosterone activation in human pancreatic β-cells stimulates insulin secretion. Diabetes. 2020. doi:10.2337/db20-0228 • PubMed • PMC full text

Kidneys & renal function

See also: Research on risk of bladder & kidney cancer

Baig MS, Kolasa-Wołosiuk A, Pilutin A, et al. Finasteride-induced inhibition of 5α-reductase type 2 could lead to kidney damage—animal, experimental study. Int J Environ Res Public Health. 2019. doi:10.3390/ijerph16101726PubMed

Da Silva MHA, Estrada JHD, Gregório BM, Sampaio FJB, De Souza DB. Does treatment with dutasteride or finasteride has [sic] impact on renal morphology? Experimental study. Acta Cir Bras. 2021. doi:10.1590/ACB360703PubMed

Tian H, Zhao C, Wu H, et al. Finasteride reduces microvessel density and expression of vascular endothelial growth factor in renal tissue of diabetic rats. Am J Med Sci. 2015. doi:10.1097/MAJ.0000000000000451PubMed